Page 3 - Dr Reddy's Laboratories Limited

Stocks to watch, July 19: Infosys, RIL, Vi, LTTS, Tata Consumer, DRL, CEAT

At 6:36 AM, GIFT Nifty futures were up 19 points, trading at 24,828.50 levels, indicating a higher start for the day.

Dr Reddy's Laboratories, Warburg Pincus, EQT frontrunners to buy BSV

Advent looking to exit 4 years after it picked up majority stake in biopharma firm

Sun Pharma, Dr Reddy's pull drugs in US over manufacturing issues: USFDA

Sun Pharma and Dr Reddy's Laboratories are recalling products in the American market due to manufacturing issues, the US Food and Drug Administration (USFDA) has said. In its latest Enforcement Report, the US health regulator stated that a US-based unit of Sun Pharma is recalling 35,069 bottles of medication used to treat high pressure inside the eye due to glaucoma or other eye diseases. New Jersey-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Xelpros (latanoprost ophthalmic emulsion) due to "out of specification for particulate matter test". The company initiated the voluntary Class III recall in the US on April 22 this year, the USFDA stated. In a separate filing, the USFDA stated that a US-based arm of Dr Reddy's Laboratories is recalling 1,176 bottles of an immunosuppressant medication. Dr Reddy's Laboratories Inc is recalling the affected lot of Sirolimus Tablets due to "Failed Impurities/Degradation Specifications", the USFDA said. The company ...

Drug makers Dr Reddy's, Sun Pharma, Aurobindo recall products in US market

Drug makers Dr Reddy's Laboratories, Sun Pharma and Aurobindo Pharma are recalling products in the US market due to manufacturing issues, as per the latest Enforcement Report of the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories is recalling close to 20,000 cartons of a medication used to control blood phenylalanine levels in adults and children. Princeton (New Jersey) based Dr Reddy's Laboratories, Inc, is recalling Javygtor (sapropterin dihydrochloride) Powder for Oral Solution (100mg) due to it being a "Sub-potent Drug", USFDA stated. The company is also recalling another lot of sapropterin dihydrochloride for the same reason, it added. The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year. As per the US health regulator, a Class I recall pertains to defective products that can cause serious health problems. The USFDA said Sun Pharma is recalling 11,016 vials of Amphotericin B Liposome for Injection, used to treat fungal ...

Dr Reddy's, Bayer partner to market second brand of Vericiguat in India

Vericiguat is currently approved for use in 35 countries

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the terms of this agreement, Dr Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands, including Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri and Adacel

Dr Reddy's Laboratories R&D facility gets VAI status in USFDA inspection

Last year in December, during the Good Manufacturing Practice (GMP) and Pre-Approval Inspection at the same facility concluded with three observations

Dr Reddy's Laboratories acquires women's health brands from MenoLabs

DRL said that it has acquired the entire MenoLabs supplements portfolio, which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause

DRL partners with Coya Therapeutics to develop nerve disorder therapy

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurological disorder characterised by progressive degeneration of nerve cells in the spinal cord and brain

Dr Reddy's Laboratories Q2 results: Net profit rises 33% to Rs 1,480 crore

The company said that the Ebitda was enabled by geographic diversification and productivity improvement in operations

Dr Reddy's Q2 results: Net profit after tax rises 33% to Rs 1,482 crore

Consolidated quarterly revenue rose 9% to 69.03 billion rupees led by a 9% growth in the key global generics segment

Dr Reddy's Lab launches generic diabetes medication in US market

Dr Reddy's Laboratories on Thursday said it has launched a generic diabetes medication in the US market. The drug major has launched Saxagliptin and Metformin Hydrochloride extended-release tablets in the US market, the Hyderabad-based company said in a statement. The company's product is a therapeutic equivalent generic version of Kombiglyze XR tablets, it added. Dr Reddy's Saxagliptin and Metformin Hydrochloride extended-release tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30, the company said.

Dr Reddy's hits new high, soars 13% in 1 month; m-cap nears Rs 1-trn mark

The stock hit a new high at Rs 5,850 on gaining 3 per cent in an otherwise weak market.

Dr Reddy's gains nearly 3% post completion of USFDA inspection at AP unit

The stock hit a fresh 52-week high at Rs 5,360, and has rallied over 19 per cent in less than two months.

Dr Reddy's Labs Q4 result: PAT up 9 times, div declared at Rs 40 per share

Its revenue from operations stood at Rs 5,843 crore in Q4 FY23, up 15.28% YoY as compared to Rs 5,068.4 crore in Q4FY22

Dr Reddy's Laboratories launches Regadenoson injection in US market

Dr Reddy's Laboratories Ltd on Friday announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market. Regadenoson injection is supplied as single-dose pre-filled syringes, 0.4mg/5ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing. The injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. In a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad. "The inspection was conducted from May 1, 2023 to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline," the company said. As per USFDA, Form 483 is issued to a

Overall breadth needs to improve for a reversal in Indian market

Over half of the Nifty 500 stocks are trading below 200-DMA, this points to a weak strength. Market breadth needs to improve if further highs are to be set

Dr Reddy's Lab Q3 net up 77% at Rs 1,247 cr, revenue from operations jump

Dr Reddy's Laboratories on Wednesday reported a 77 per cent increase in its consolidated net profit at Rs 1,247 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 706 crore in the October-December period of the previous fiscal. Revenue from operations rose to Rs 6,770 crore during the period under review as against Rs 5,320 crore in the year-ago period, Dr Reddy's Laboratories said in a regulatory filing.

Claims against Dr Reddy's Laboratories over Revlimid in US dismissed

Dr Reddy's Laboratories on Thursday said all claims against it in the antitrust litigation filed in the US, related to a prescription medicine Revlimid, used in treatment of multiple myeloma have been dismissed. In a regulatory filing, the company said on December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories, Inc. respectively, from the case. "All claims against the company in the litigation have now been dismissed," Dr Reddy's said. Last month the company had stated that it was among several generic pharmaceutical companies, including Celgene and Bristol Myers Squibb, against which an antitrust litigation has been filed in the District of New Jersey, USA. The complaint had asserted "claims under federal and state antitrust law and other state laws alleging that defendants improperly restrained competition and maintained a shared monopoly in the sale of brand and generic Revlimid in the United States."

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up